graves'%20disease
GRAVES' DISEASE
Graves' disease is an autoimmune disorder that results into overproduction of thyroid hormones.
Thyrotoxicosis signs and symptoms include hyperactivity, irritability, insomnia, dysphoria, sweating, heat intolerance, palpitations, weakness, fatigue, weight loss despite increased appetite, diarrhea, steatorrhea polyuria, decreased libido, tachycardia, tremor, goiter, alopecia, gynecomastia, eyelid lag or retraction and rarely periodic paralysis.
Clinical features in thyrotoxic patient that suggests Graves's disease are ophthalmopathy, thyroid dermopathy, thyroid acropachy, diffuse goiter, antibodies to thyroid peroxidase or thyroglobulin and thyroid radionuclide scan demonstrating a diffuse goiter.

Follow Up

Radioactive Iodine Therapy
  • Follow up w/in 1-2 mth after therapy w/ assessment of free T4 & total T3
Patient Education
  • Instructions on radiation safety precautions immediately following treatment
Hypothyroidism (Permanent or Transient)
  • Transient
    • Usually occurs w/in 2 mth of therapy & lasts for 1-4 mth
    • May choose not to treat
  • Permanent
    • Treat w/ Levothyroxine
Worsening of Eye Disease
  • May occur w/ radioiodine therapy
  • Often transient
  • May be prevented w/ the administration of Prednisolone
Follow Up Exams
  • Every 4-6 wk until euthyroid & condition has stabilized
  • Then 3 mth, 6 mth, then annually based on physician’s judgment
Pharmacological therapy
Follow Up Exams
  • Every 2-3 mth x 2 yr
  • Then annually to check for recurrence

Surgical Therapy
Hypothyroid

  • Patients may become hypothyroid esp w/ total thyroidectomy
  • Treat w/ Levothyroxine
Follow Up Exams
  • As required
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 20 Jul 2018
Women with pre-eclampsia or gestational hypertension during their first pregnancy had an increased risk of developing chronic hypertension, type 2 diabetes (T2D), and hypercholesterolaemia than those who were normotensive during pregnancy, according to a study. The risk persisted for several decades later, signalling these hypertensive disorders of pregnancy (HDP) as red flags for cardiovascular (CV) health for life.
Roshini Claire Anthony, 30 Jul 2018

Canagliflozin may provide a renoprotective effect in individuals with type 2 diabetes (T2D) and a history of cardiovascular disease (CVD), according to results from the CANVAS* Program.

Stephen Padilla, 31 Jul 2018
Patients with type 2 diabetes (T2D) treated with sulphonylureas as second-line drugs are at an increased risk of myocardial infarction (MI), all-cause mortality and severe hypoglycaemia compared with those who remained on metformin monotherapy, a recent study has found.
22 Jul 2018
There appears to be a nonlinear relationship between total oestradiol and free oestradiol and all-cause mortality among older men, according to data from the Three-City cohort study. Specifically, the association is stronger for cardiovascular disease mortality and nonexistent for cancer mortality.